Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2005

01-09-2005 | Review

Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis

Authors: Jon T Giles, Verônica Fernandes, Joao AC Lima, Joan M Bathon

Published in: Arthritis Research & Therapy | Issue 5/2005

Login to get access

Abstract

Data from population- and clinic-based epidemiologic studies of rheumatoid arthritis patients suggest that individuals with rheumatoid arthritis are at risk for developing clinically evident congestive heart failure. Many established risk factors for congestive heart failure are over-represented in rheumatoid arthritis and likely account for some of the increased risk observed. In particular, data from animal models of cytokine-induced congestive heart failure have implicated the same inflammatory cytokines produced in abundance by rheumatoid synovium as the driving force behind maladaptive processes in the myocardium leading to congestive heart failure. At present, however, the direct effects of inflammatory cytokines (and rheumatoid arthritis therapies) on the myocardia of rheumatoid arthritis patients are incompletely understood.
Appendix
Available only for authorised users
Literature
1.
Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2407-2415.PubMed
2.
Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003, 349: 2399-2406.PubMed
3.
del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001, 44: 2737-2745.PubMed
4.
Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999, 26: 2562-2571.PubMed
5.
Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol. 2003, 30: 36-40.PubMed
6.
de Lemos JA, Hennekens CH, Ridker PM: Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol. 2000, 36: 423-426.PubMed
7.
Wallberg-Jonsson S, Cederfelt M, Rantapaa DS: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol. 2000, 27: 71-75.PubMed
8.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000, 101: 1767-1772.PubMed
9.
Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002, 359: 1173-1177.PubMed
10.
Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup , et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol. 2001, 38: 2101-2113.PubMed
11.
Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997, 133: 703-712.PubMed
12.
Schocken DD, Arrieta MI, Leaverton PE, Ross EA: Prevalence and mortality-rate of congestive-heart-failure in the United-States. J Am Coll Cardiol. 1992, 20: 301-306.PubMed
13.
Haldeman GA, Croft JB, Giles WH, Rashidee A: Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 1999, 137: 352-360.PubMed
14.
Alexander M, Grumbach K, Remy L, Rowell R, Massie BM: Congestive heart failure hospitalizations and survival in California: Patterns according to race ethnicity. Am Heart J. 1999, 137: 919-927.PubMed
15.
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002, 347: 1397-1402.PubMed
16.
Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. J Am Med Assoc. 2004, 292: 344-350.
17.
Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JC, Stricker BH: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam study. Eur Heart J. 2004, 25: 1614-1619.PubMed
18.
Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999, 159: 29-34.PubMed
19.
Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart-failure: the Framingham-study. J Am Coll Cardiol. 1993, 22: A6-A13.
20.
Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998, 98: 2282-2289.PubMed
21.
Mckee PA, Castelli WP, Mcnamara PM, Kannel WB: Natural history of congestive heart failure: Framingham study. N Engl J Med. 1971, 285: 1441-1446.PubMed
22.
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D: Lifetime risk for developing congestive heart failure: The Framingham heart study. Circulation. 2002, 106: 3068-3072.PubMed
23.
O'Connell JB: The economic burden of heart failure. Clin Cardiol. 2000, 23: 6-10.
24.
Gabriel SE, Crowson CS, O'Fallon WM: Comorbidity in arthritis. J Rheumatol. 1999, 26: 2475-2479.PubMed
25.
Kremers H, Nicola P, Crowson C, Ballman K, Gabriel SE: Risk of heart failure among patients with rheumatoid arthritis. Arthritis Rheum. 2003, 48: S706-
26.
Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE: The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum. 2005, 52: 412-420.PubMed
27.
Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med. 2004, 116: 305-311.PubMed
28.
Mutru O, Laakso M, Isomaki H, Koota K: Cardiovascular mortality in patients with rheumatoid-arthritis. Cardiology. 1989, 76: 71-77.PubMed
29.
Nicola P, Crowson CS, Maradit-Kremers H, Gabriel SE: Is congestive heart failure the major contributor of the increased mortality in rheumatoid arthritis?. Arthritis Rheum. 2004, 50: S674-
30.
Remes J, Miettinen H, Reunanen A, Pyorala K: Validity of clinical-diagnosis of heart-failure in primary health-care. Eur Heart J. 1991, 12: 315-321.PubMed
31.
Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. J Am Med Assoc. 1996, 275: 1557-1562.
32.
Cathcart ES, Spodick DH: Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. J Med. 1962, 266: 959-964.
33.
Turner LW, Lansbury J: Low diastolic pressure as a clinical feature of rheumatoid arthritis and its possible etiologic significance. Am J Med Sci. 1954, 227: 503-508.PubMed
34.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307.PubMed
35.
McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 640-644.
36.
Pope JE, Anderson JJ, Felson DT: A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood-pressure. Arch Intern Med. 1993, 153: 477-484.PubMed
37.
Kannel WB, Abbott RD: Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med. 1984, 311: 1144-1147.PubMed
38.
Elhendy A, Schinkel AFL, van Domburg RT, Bax JJ, Poldermans D: Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease. J Nucl Cardiol. 2004, 11: 527-533.PubMed
39.
Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, Nam CM, Lee SK: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002, 46: 1714-1719.PubMed
40.
Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC: Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000, 35: 1628-1637.PubMed
41.
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001, 161: 996-1002.PubMed
42.
Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H: No association between rheumatoid arthritis and insulin dependent diabetes mellitus: An epidemiologic and immunogenetic study. J Rheumatol. 1992, 19: 856-858.PubMed
43.
Arnlov J, Lind L, Zethelius B, Andren B, Hales CN, Vessby B, Lithell H: Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001, 142: 720-724.PubMed
44.
Dessein P, Stanwix A, Joffe B: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002, 4: R5-PubMedCentralPubMed
45.
Svenson KLG, Pollare T, Lithell H, Hallgren R: Impaired glucose handling in active rheumatoid-arthritis: Relationship to peripheral insulin resistance. Metabolism. 1988, 37: 125-130.PubMed
46.
Lebowitz WB: Heart in rheumatoid arthritis (rheumatoid disease): a clinical and pathologicalstudy of 62 cases. Ann Intern Med. 1963, 58: 102-PubMed
47.
Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat AC, Boissier MC: Cardiac manifestations of rheumatoid arthritis: A case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 2001, 45: 129-135.PubMed
48.
Iveson JM, Thadani U, Ionescu M, Wright V: Aortic valve incompetence and replacement in rheumatoid arthritis. Ann Rheum Dis. 1975, 34: 312-320.PubMedCentralPubMed
49.
Chand EM, Freant LJ, Rubin JW: Aortic valve rheumatoid nodules producing clinical aortic regurgitation and a review of the literature. Cardiovasc Pathol. 1999, 8: 333-338.PubMed
50.
Boxt LM: MR imaging of pulmonary hypertension and right ventricular dysfunction. Magn Reson Imaging Clin N Am. 1996, 4: 307-325.PubMed
51.
Zitnik RJ, Cooper JAD: Pulmonary-disease due to anti-rheumatic agents. Clin Chest Med. 1990, 11: 139-150.PubMed
52.
Turesson C, Jacobsson LTH: Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004, 33: 65-72.PubMed
53.
Radoux V, Menard HA, Begin R, Decary F, Koopman WJ: Airways disease in rheumatoid-arthritis patients: one element of a general exocrine dysfunction. Arthritis Rheum. 1987, 30: 249-256.PubMed
54.
Zrour SH, Touzi M, Bejia I, Golli M, Rouatbi N, Sakly N, Younes M, Tabka Z, Bergaoui N: Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis: Prospective study in 75 patients. Joint Bone Spine. 2005, 72: 41-47.PubMed
55.
Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Ollier WER, Gonzalez-Gay MA: Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum. 2004, 33: 231-238.PubMed
56.
Dawson JK, Goodson NG, Graham DR, Lynch MP: Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology. 2000, 39: 1320-1325.PubMed
57.
Keser G, Capar I, Aksu K, Inal V, Danaoglu Z, Savas R, Oksel F, Tunc E, Kabasakal Y, Kitapcioglu G, Doganavsargil E: Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol. 2004, 33: 244-245.PubMed
58.
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier NF, O'Connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease. Cross-sectional results of the sleep heart health study. Am J Resp Crit Care Med. 2001, 163: 19-25.PubMed
59.
Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000, 342: 1378-1384.PubMed
60.
Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R: Pulmonary hemodynamics in the obstructive sleep apnea syndrome: Results in 220 consecutive patients. Chest. 1996, 109: 380-386.PubMed
61.
Hayashi M, Fujimoto K, Urushibata K, Uchikawa Si, Imamura H, Kubo K: Nocturnal oxygen desaturation correlates with the severity of coronary atherosclerosis in coronary artery disease. Chest. 2003, 124: 936-941.PubMed
62.
Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, Adachi M: Elevated production of tumor necrosis factor-{alpha} by monocytes in patients with obstructive sleep apnea syndrome. Chest. 2004, 126: 1473-1479.PubMed
63.
Redlund-Johnell I: Upper airway obstruction in patients with rheumatoid arthritis and temporomandibular joint destruction. Scand J Rheumatol. 1988, 17: 273-279.PubMed
64.
Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ: Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis. 2004, 63: 88-90.PubMedCentralPubMed
65.
Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP: Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-{alpha} antagonist. J Clin Endocrinol Metab. 2004, 89: 4409-4413.PubMed
66.
Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, Silman AJ: Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum. 1997, 40: 1955-1961.PubMed
67.
Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, Kannel WB, Vasan RS: Obesity and the risk of heart failure. N Engl J Med. 2002, 347: 305-313.PubMed
68.
Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH: Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA. 2000, 97: 1784-1789.PubMedCentralPubMed
69.
Gvozdjakova A, Kucharska J, Gvozdjak J: Effect of smoking on the oxidative processes of cardiomyocytes. Cardiology. 1992, 81: 81-84.PubMed
70.
Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid cachexia: Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest. 1994, 93: 2379-2386.PubMedCentralPubMed
71.
Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000, 342: 1077-1084.PubMed
72.
Sokoloff L: Cardiac involvement in rheumatoid arthritis and allied disorders: Current concepts. Mod Concepts Cardiovasc Dis. 1964, 32: 847-850.
73.
Abbas A, Byrd BF: Right-sided heart failure due to right ventricular cavity obliteration by rheumatoid nodules. Am J Cardiol. 2000, 86: 711-712.PubMed
74.
Ojeda VJ, Stuckey BGA, Owen ET, Walters MNI: Cardiac rheumatoid nodules. Med J Australia. 1986, 144: 92-93.PubMed
75.
Peter H, Bernd S, Thomas G, Jurgen S, Ulf M: Fatal outcome of constrictive pericarditis in rheumatoid arthritis. Rheumatol Int. 2003, 23: 312-314.
76.
Yurchak PM, Deshpande V: Case 2–2003: A 60-year-old man with mild congestive heart failure of uncertain cause. N Engl J Med. 2003, 348: 243-249.PubMed
77.
Slack JD, Waller B: Acute congestive-heart-failure due to the arteritis of rheumatoid-arthritis: Early diagnosis by endomyocardial biopsy – a case-report. Angiology. 1986, 37: 477-482.PubMed
78.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D: Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med. 1997, 336: 1350-1355.PubMed
79.
Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The Cardiovascular Health Study. J Am Coll Cardiol. 2004, 43: 2207-2215.PubMed
80.
Lauer MS, Evans JC, Levy D: Prognostic implications of subclinical left-ventricular dilatation and systolic dysfunction in men free of overt cardiovascular-disease (the Framingham heart-study). Am J Cardiol. 1992, 70: 1180-1184.PubMed
81.
The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991, 325: 293-302.
82.
Wang TJ, Levy D, Benjamin EJ, Vasan RS: The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med. 2003, 138: 907-916.PubMed
83.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999, 33: 1948-1955.PubMed
84.
Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002, 105: 1387-1393.PubMed
85.
Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D: Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol. 2001, 37: 1042-1048.PubMed
86.
Mustonen J, Laakso M, Hirvonen T, Mutru O, Pirnes M, Vainio P, Kuikka JT, Rautio P, Lansimies E: Abnormalities in left-ventricular diastolic function in male-patients with rheumatoid-arthritis without clinically evident cardiovascular-disease. Eur J Clin Invest. 1993, 23: 246-253.PubMed
87.
Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A: QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol. 2002, 31: 22-26.PubMed
88.
Corrao S, Salli L, Arnone S, Scaglione R, Pinto A, Licata G: Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest. 1996, 26: 293-297.PubMed
89.
Wislowska M, Sypula S, Kowalik I: Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol. 1998, 17: 369-377.PubMed
90.
Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, Finardi G: Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol. 1999, 17: 407-412.PubMed
91.
Wislowska M, Sypula S, Kowalik I: Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int. 1999, 18: 163-169.PubMed
92.
Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L, Taccari E, Musca A: Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis. 2000, 59: 227-229.PubMed
93.
Alpaslan M, Onrat E, Evcik D: Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin Rheumatol. 2003, 22: 84-88.PubMed
94.
Levendoglu F, Temizhan A, Ugurlu H, Ozdemir A, Yazici M: Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int. 2004, 24: 141-146.PubMed
95.
Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure: Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004, 350: 1953-1959.PubMed
96.
Petrie MC, Hogg K, Caruana L, McMurray JJV: Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: Is there a reliable echocardiographic measure of diastolic dysfunction?. Heart. 2004, 90: 511-517.PubMedCentralPubMed
97.
Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PWF, Levy D: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. J Am Med Assoc. 2002, 288: 1252-1259.
98.
Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004, 350: 655-663.PubMed
99.
Yasuda M, Yasuda D, Tomooka K, Nobunaga M: Plasma concentration of human atrial natriuretic hormone in patients with connective-tissue diseases. Clin Rheumatol. 1993, 12: 231-235.PubMed
100.
Shichiri M, Miyasaka N, Hirata Y, Ando K, Marumo F: Appearance of beta-human atrial-natriuretic-peptide in collagen disease. J Endocrinol. 1991, 130: 159-161.PubMed
101.
Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PW: Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. J Am Med Assoc. 2003, 289: 1251-1257.
102.
Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, Wilson PW, Vasan RS: Relations of plasma homocysteine to left ventricular structure and function: The Framingham heart study. Eur Heart J. 2004, 25: 523-530.PubMed
103.
Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med. 1998, 338: 1042-1050.PubMed
104.
Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvst S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002, 29: 875-882.PubMed
105.
Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapaa-Dahlqvist S: Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol. 2003, 32: 205-210.PubMed
106.
Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005, 52: 262-267.PubMed
107.
Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST). Circulation. 2001, 103: 2055-2059.PubMed
108.
Kubota T, Miyagishima M, Alvarez RJ, Kormos R, Rosenblum WD, Demetris AJ, Semigran MJ, Dec GW, Holubkov R, McTiernan CF, et al: Expression of proinflammatory cytokines in the failing human heart: Comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000, 19: 819-824.PubMed
109.
Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor-necrosis-factor in severe chronic heart-failure. N Engl J Med. 1990, 323: 236-241.PubMed
110.
Rauchhaus M, Doehner W, Francis DP, Kemp M, Nicbauer J, Volk HD, Coats AJS, Anker SD: Cytokine parameters predict increased mortality in patients with chronic heart failure. Eur Heart J. 2000, 21: 233-
111.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996, 27: 1201-1206.PubMed
112.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996, 93: 704-711.PubMed
113.
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham heart study. Circulation. 2003, 107: 1486-1491.PubMed
114.
Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M: Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation. 2003, 108: 2317-2322.PubMed
115.
Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton PJ, Polak JM, Pepper JR: Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation. 2001, 104: 233-240.
116.
Birks EJ, Burton PBJ, Owen V, Mullen AJ, Hunt D, Banner NR, Barton PJ, Yacoub MH: Elevated tumor necrosis factor-{alpha} and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation. 2000, 102: 352-358.
117.
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593.PubMed
118.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000, 343: 1594-1602.PubMed
119.
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259.PubMed
120.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha mono-clonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003, 48: 35-45.PubMed
121.
Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005, 16: 489-495.PubMed
122.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Randomized, double-blind, placebo-controlled, pilot trial of Inflix-imab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation. 2003, 107: 3133-3140.PubMed
123.
Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al: Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004, 109: 1594-1602.PubMed
124.
Khanna D, McMahon M, Furst DE: Anti-tumor necrosis factor a therapy and heart failure: What have we learned and where do we go from here?. Arthritis Rheum. 2004, 50: 1040-1050.PubMed
125.
Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005, 44: 677-680.
126.
Hochreiter CA, Carter J, Herrold EMM, Warren MS, Whitmore J, Borer JS: Treatment with Etanercept (Enbrel) does not affect left ventricular ejection fraction (LVEF) in patients with chronic heart failure. Arthritis Rheum. 2003, 48: s120-
127.
Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG: Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res. 1990, 67: 753-763.PubMed
128.
Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock K, Glembotski CC, Quintana PJ, Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes.Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996, 98: 2854-2865.PubMedCentralPubMed
129.
Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989, 321: 280-287.PubMed
130.
Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998, 97: 1382-1391.PubMed
131.
Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM: Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Am Coll Cardiol. 1997, 29: 29165-
132.
Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-{alpha}. Circulation. 1998, 97: 1375-1381.PubMed
133.
Li X, Moody MR, Engel D, Walker S, Clubb FJ, Sivasubramanian N, Mann DL, Reid MB: Cardiac-specific overexpression of tumor necrosis factor-{alpha} causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000, 102: 1690-1696.PubMed
134.
Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF: Anti-tumor necrosis factor-{alpha} antibody limits heart failure in a transgenic model. Circulation. 2001, 104: 1094-1097.PubMed
135.
Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA. 2000, 97: 12746-12751.PubMedCentralPubMed
136.
Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, Demayo FJ, Spinale FG, Mann DL: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001, 104: 826-831.PubMed
137.
Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling – concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000, 35: 569-582.PubMed
138.
Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG: Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002, 8: 390-398.PubMed
139.
Coker ML, Jolly JR, Joffs C, Etoh T, Holder JR, Bond BR, Spinale FG: Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol. 2001, 281: H543-H551.PubMed
140.
Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG: Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol. 1998, 274: H1516-H1523.PubMed
141.
Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G: Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. EurJ Clin Invest. 2003, 33: 648-656.
142.
Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy M, Schulz R: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res. 2003, 57: 426-433.PubMed
143.
Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol. 2000, 32: 109-120.PubMed
144.
Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation. 2001, 103: 2303-2309.PubMed
145.
Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM: MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 2002, 282: H983-H989.PubMed
146.
Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, Demayo FJ, Spinale FG, Mann DL: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001, 104: 826-831.PubMed
147.
Berry MF, Woo YJ, Pirolli TJ, Bish LT, Moise MA, Burdick JW, Morine KJ, Jayasankar V, Gardner TJ, Sweeney HL: Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant. 2004, 23: 1061-1068.PubMed
148.
Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation. 2003, 107: 984-991.PubMed
149.
Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, Robbins PD, McTiernan CF, Feldman AM: Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 2000, 101: 2518-2525.PubMed
150.
Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997, 385: 729-733.PubMed
151.
Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL: Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2003, 109: 262-268.PubMed
152.
Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, Spinale FG, Feuerstein G, Sivasubramanian N, Mann DL: Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation. 2003, 108: 1002-1008.PubMed
153.
Satoh M, Nakamura M, Saitoh H, Satoh H, Maesawa C, Segawa I, Tashiro A, Hiramori K: Tumor necrosis factor-{alpha} converting enzyme and tumor necrosis factor-{alpha} in human dilated cardiomyopathy. Circulation. 1999, 99: 3260-3265.PubMed
154.
Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, Hiramori K: Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol. 2000, 36: 1288-1294.PubMed
Metadata
Title
Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis
Authors
Jon T Giles
Verônica Fernandes
Joao AC Lima
Joan M Bathon
Publication date
01-09-2005
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2005
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1814

Other articles of this Issue 5/2005

Arthritis Research & Therapy 5/2005 Go to the issue

Commentary

Opioids for non-operable osteoarthritis and soft-tissue rheumatism

Commentary

MAPK signalling in rheumatoid joint destruction: can we unravel the puzzle?

Review

Primary and secondary autoimmune neutropenia

Research article

Association of ENPP1gene polymorphisms with hand osteoarthritis in a Chuvasha population

Commentary

Crystals in hand

Commentary

Somatic mutations in mitochondria: the chicken or the egg?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits